Search results for "Cost-benefit analysi"

showing 10 items of 148 documents

Design, Calibration, and Application of a Robust, Cost-Effective, and High-Resolution Lensless Holographic Microscope

2022

Lensless holographic microscope (LHM) is an emerging very promising technology that provides high-quality imaging and analysis of biological samples without utilizing any lens for imaging. Due to its small size and reduced price, LHM can be a very useful tool for the point-of-care diagnosis of diseases, sperm assessment, or microfluidics, among others, not only employed in advanced laboratories but also in poor and/or remote areas. Recently, several LHMs have been reported in the literature. However, complete characterization of their optical parameters remains not much presented yet. Hence, we present a complete analysis of the performance of a compact, reduced cost, and high-resolution LH…

Microscopyin-line holographic microscopy; digital holography; Gabor holography; lensless microscope; digital image processing; medical and biological imaging; microscope characterizationCost-Benefit Analysisin-line holographic microscopyChemical technologyHolographyTP1-1185microscope characterizationÒpticaOptometriadigital image processingdigital holographyBiochemistryArticleAtomic and Molecular Physics and OpticsAnalytical ChemistryGabor holographylensless microscopeCalibrationmedical and biological imagingElectrical and Electronic EngineeringInstrumentationLenses
researchProduct

Economic evaluations of ergonomic interventions preventing work-related musculoskeletal disorders: a systematic review of organizational-level interv…

2017

Background Work-related musculoskeletal disorders (WMSD) represent a major public health problem and economic burden to employers, workers and health insurance systems. This systematic review had two objectives: (1) to analyze the cost-benefit results of organizational-level ergonomic workplace-based interventions aimed at preventing WMSD, (2) to explore factors related to the implementation process of these interventions (obstacles and facilitating factors) in order to identify whether economic results may be due to a successful or unsuccessful implementation. Methods Systematic review. Studies were searched in eight electronic databases and in reference lists of included studies. Companio…

Mixed methodsCost effectivenessCost-Benefit AnalysisApplied psychologyPsychological interventionCost-benefitInterventionOccupational safety and health03 medical and health sciences0302 clinical medicineMedicineHumansGeneralizability theory030212 general & internal medicineMusculoskeletal DiseasesOccupational HealthRandomized Controlled Trials as TopicOccupationbusiness.industryWork-related musculoskeletal disordersPreventionlcsh:Public aspects of medicinePublic Health Environmental and Occupational HealthHuman factors and ergonomicslcsh:RA1-1270Evidence-based medicine030210 environmental & occupational healthEconomic evaluation3. Good healthOccupational Diseases8. Economic growthEconomic evaluationSystematic reviewCost-effectivenessErgonomicsbusinessWork-related musculoskeletal disordersResearch ArticleBMC Public Health
researchProduct

Nanostructured medical sutures with antibacterial properties

2014

Bacterial repellence in suture materials is a desirable property that can potentially improve the healing process by preventing infection. We describe a method for generating nanostructures at the surface of commercial sutures of different composition, and their potential for preventing biofilm formation. We show how bacteria attachment is altered in the presence of nanosized topographies and identify optimum designs for preventing it without compromising biocompatibility and applicability in terms of nanostructure robustness or tissue friction. These studies open new possibilities for flexible and cost-effective realization of topography-based antibacterial coatings for absorbable biomedic…

NanostructureMaterials scienceBiocompatibilityPolymersSurface PropertiesCost-Benefit AnalysisBiophysicsBiocompatible MaterialsBioengineeringPlasma treatmentNanotechnologyBacterial AdhesionBiomaterialsBiofoulingMiceDrug Delivery SystemsEscherichia coliAnimalsSuturesAnti-Bacterial AgentsNanostructuresOxygenMechanics of MaterialsBiofilmsMicroscopy Electron ScanningCeramics and CompositesFemaleStress MechanicalChickensBiomedical engineeringBiomaterials
researchProduct

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fet…

2015

The lifetime utility of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is still controversial. The aim of this study was to ascertain when LT is cost-effective for HCC patients, with a view to proposing new transplant selection criteria. The study involved a real cohort of potentially transplantable Italian HCC patients (n = 2419 selected from the Italian Liver Cancer group database) who received nontransplant therapies. A non-LT survival analysis was conducted, the direct costs of therapies were calculated, and a Markov model was used to compute the cost utility of LT over non-LT therapies in Italian and US cost scenarios. Post-LT survival was calculated using t…

OncologyMaleTime FactorsDatabases Factualmedicine.medical_treatmentCost-Benefit AnalysisLiver transplantationClinical endpointLiver NeoplasmsSurgery; Transplantation; HepatologyHealth Care Costshepatocellular carcinomaMiddle AgedMarkov ChainsTumor BurdenModels EconomicTreatment OutcomeItalyHepatocellular carcinomaFemaleQuality-Adjusted Life Yearsalpha-FetoproteinsAlpha-fetoproteinMonte Carlo Methodmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADecision Support Techniquesalpha-fetoproteinPredictive Value of TestsInternal medicinemedicineHumansneoplasmsSurvival analysisAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologyProportional hazards modelbusiness.industryPatient SelectionRetrospective cohort studymedicine.diseaseSurvival Analysisdigestive system diseasesUnited StatesSurgeryLiver TransplantationTransplantationMultivariate AnalysisSurgerybusiness
researchProduct

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.

2021

To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harboring EGFR mutations.A partitioned survival model was developed to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) from the perspective of the Spanish National Health System. Two Bayesian NMAs were performed independently, by using the polynomial fraction method to fit Kaplan-Meier curves for overall survival and progression-free survival. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty.The ICER was calculated for the fou…

Oncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLung NeoplasmsCost effectivenessAfatinibCost-Benefit AnalysisAfatinibchemistry.chemical_compoundErlotinib HydrochlorideGefitinibInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansheterocyclic compoundsPharmacology (medical)OsimertinibLung cancerneoplasmsProtein Kinase Inhibitorsbusiness.industryHealth PolicyBayes TheoremGefitinibGeneral MedicineCost-effectiveness analysismedicine.diseaseDacomitinibrespiratory tract diseasesErbB ReceptorschemistryMutationErlotinibbusinessmedicine.drugExpert review of pharmacoeconomicsoutcomes research
researchProduct

Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies.

2013

Cancer of the pancreas is the second most frequent digestive cancer in the US, accounting for about 44,000 new cases per year. In Europe, it is the sixth most frequent cancer, accounting for 2.8% of cancers in men and 3.2% in women. With a five-year survival of less than 10%, it is the fifth leading cause of cancer-related death. The majority of cases are diagnosed above the age of 65 and in about 60% of cases at an advanced stage, explaining that little improvement has been observed in survival over the past 30 years. Radical surgery offers the only curative treatment of pancreatic cancer. Alternative or combined therapeutic options in particular consist of adjuvant or neoadjuvant chemothe…

Oncologymedicine.medical_specialtyCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisAntineoplastic AgentsQuality of lifePancreatic cancerInternal medicineAdjuvant therapyMedicineCombined Modality TherapyHumansRadical surgeryIntensive care medicineDigestive System Surgical Proceduresbusiness.industryPalliative CareGastroenterologyCancermedicine.diseaseCombined Modality TherapyRadiation therapyEconomics MedicalEuropePancreatic NeoplasmsQuality of LifeHealth ResourcesbusinessBest practiceresearch. Clinical gastroenterology
researchProduct

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

2019

Aim: Osimertinib improves progression-free survival in first-line EGFR mutation–positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted life-year (QALY) and incremental cost–effectiveness ratio when treating with osimertinib versus standard first-line tyrosine kinase inhibitors (TKIs). Results: Osimertinib presented higher QALYs (0.61) compared with standard EGFR–TKIs (0.42). Osimertinib costs were €83,258.99, in comparison with €29,209.45 for the standard EGFR–TKIs. An incremental cost–effectiveness ratio of €273,895.36/QALY was obtained for osimertinib. Conclusion: Osimerti…

Oncologymedicine.medical_specialtyLung NeoplasmsCost effectivenessCost-Benefit AnalysisAntineoplastic Agents03 medical and health scienceschemistry.chemical_compoundEgfr tki0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansOsimertinib030212 general & internal medicineLung cancerProtein Kinase Inhibitorshealth care economics and organizationsAcrylamidesAniline Compoundsbusiness.industryHealth PolicyCost-effectiveness analysismedicine.diseaseMarkov ChainsDacomitinibrespiratory tract diseasesErbB ReceptorsFirst line treatmentchemistry030220 oncology & carcinogenesisMutationQuality-Adjusted Life YearsNon small cellbusinessModels EconometricJournal of Comparative Effectiveness Research
researchProduct

Economic and Financial Comparison between Organic and Conventional Farming in Sicilian Lemon Orchards

2015

Sicily has a long tradition in citrus fruit cultivations that with vineyard and olive tree represent the main Mediterranean tree crops. In this paper we have evaluated the economic and financial sustainability of lemon production, both in organic farming and in conventional farming

Organic productlemonlcsh:TJ807-830Geography Planning and Developmentlcsh:Renewable energy sourcesEcological farmingagricultural practicesManagement Monitoring Policy and Lawcost-benefit analysiAgricultural scienceorganic farmingjel:QSettore AGR/01 - Economia Ed Estimo Ruraleagricultural practices; cost-benefit analysis; lemon; organic farming; profitabilityEconomicsNatural farmingprofitabilitylcsh:Environmental scienceslcsh:GE1-350Renewable Energy Sustainability and the EnvironmentAgroforestryIntensive farmingcost-benefit analysislcsh:Environmental effects of industries and plantsjel:Q0jel:Q2jel:Q3jel:Q5lcsh:TD194-195agricultural practiceIntensive crop farmingjel:O13Extensive farmingOrganic farmingjel:Q56Mixed farmingSustainability
researchProduct

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation

2021

Objectives: Optimized diagnostic algorithms to detect active infections are crucial to achieving HCV elimination. We evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis, in a context of a high endemic country for HCV infection. Methods: A Markov disease progression model, simulating six diagnostic algorithms in the birth cohort 1969‐1989 over a 10‐year horizon from a healthcare perspective was used. Conventionally diagnosis of active HCV infection is through detection of antibodies (HCV‐Ab) detection followed by HCV‐RNA or HCV core antigen (HCV‐Ag) confirmatory testing either on a second sample or by same sample reflex testing. The …

Pediatricsmedicine.medical_specialtyCost effectivenessCost-Benefit Analysiscost-effectiveneContext (language use)HepacivirusAntiviral AgentsLiver diseaseMedicineHumansbusinesshealth care economics and organizationsHepatologybusiness.industryscreeningDisease progressionHCV chronic infectionvirus diseasesDiagnostic algorithmshealthHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CHcv eliminationdigestive system diseasesWHO targetHcv core antigenbusinessAlgorithms
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct